Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma

The EML4-ALK fusion defines a new molecular subset of NSCLC that has distinct clinical and bronchoscopic findings suggesting more proximal origin when compared to tumours harbouring EGFR mutations.